Press Release Details
Twist Bioscience Adopts Battelle’s ThreatSEQ™ DNA Screening Web Service for Advanced Biosecurity
“We have spent decades working with and characterizing biothreats to
support global biodefense efforts, which has resulted in the curation of
a high-quality Sequence of Concern database and the development of a
robust algorithm for screening DNA at production scale rapidly,” said
ThreatSEQ web service is a first of-its-kind commercial DNA screening solution that is highly accurate and cost effective. The service includes an advanced biocuration pipeline that reduces synthesis providers’ maintenance and labor costs while maintaining effective biosecurity. The platform does this by streamlining the review process through an industry-oriented user interface to review screening results, which displays high-quality metadata and a graphical representation of genomic context.
“We have worked with Battelle on the FunGCAT
program for more than two years, where we have developed an even greater
appreciation for its cutting-edge computational and laboratory-based
approaches to screening,” said Emily M. Leproust, Ph.D., CEO and
co-founder of
About Battelle
Every day, the people of Battelle apply science and technology to
solving what matters most. At major technology centers and national
laboratories around the world, Battelle conducts research and
development, designs and manufactures products, and delivers critical
services for government and commercial customers. Headquartered in
About
Follow us on Twitter
|
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, the potential evolutions of Twist Bioscience’s
biosecurity program. Such forward-looking statements involve known and
unknown risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the risks and
uncertainties of the ability to attract new customers and retain and
grow sales from existing customers; risks and uncertainties of rapidly
changing technologies and extensive competition in synthetic biology
could make the products
View source version on businesswire.com: https://www.businesswire.com/news/home/20190409005349/en/
Source:
Twist Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com
Twist Media Contact:
Angela Bitting
925- 202-6211
media@twistbioscience.com
Battelle Media Contact:
Katy Delaney
delaneyk@battelle.org
Battelle Product Inquiries:
threatseq@battelle.org